
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
SMI announced the launch of SMI Clinical Trials, a patient recruitment division designed to accelerate the clinical trial recruitment and enrollment process and reduce per-patient recruitment costs.






